Determinants of Patient-Oncologist Prognostic Discordance in Advanced Cancer

Robert Gramling, Kevin Fiscella, Guibo Xing, Michael Hoerger, Paul Duberstein, Sandy Plumb, Supriya Mohile, Joshua J Fenton, Daniel J Tancredi, Richard L Kravitz, Ronald M. Epstein

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Design, Setting, and Participants: Cross-sectional study conducted at academic and community oncology practices in Rochester, New York, and Sacramento, California. The sample comprises 236 patients with advanced cancer and their 38 oncologists who participated in a randomized trial of an intervention to improve clinical communication. Participants were enrolled from August 2012 to June 2014 and followed up until October 2015.

Importance: Patients with advanced cancer often report expectations for survival that differ from their oncologists' expectations. Whether patients know that their survival expectations differ from those of their oncologists remains unknown. This distinction is important because knowingly expressing differences of opinion is important for shared decision making, whereas patients not knowing that their understanding differs from that of their treating physician is a potential marker of inadequate communication.

Objective: To describe the prevalence, distribution, and proportion of prognostic discordance that is due to patients' knowingly vs unknowingly expressing an opinion that differs from that of their oncologist.

Main Outcomes and Measures: We ascertained discordance by comparing patient and oncologist ratings of 2-year survival probability. For discordant pairs, we determined whether patients knew that their opinions differed from those of their oncologists by asking the patients to report how they believed their oncologists rated their 2-year survival.

Results: Among the 236 patients (mean [SD] age, 64.5 [11.4] years; 54% female), 161 patient-oncologist survival prognosis ratings (68%; 95% CI, 62%-75%) were discordant. Discordance was substantially more common among nonwhite patients compared with white patients (95% [95% CI, 86%-100%] vs 65% [95% CI, 58%-73%], respectively; P = .03). Among 161 discordant patients, 144 (89%) did not know that their opinions differed from that of their oncologists and nearly all of them (155 of 161 [96%]) were more optimistic than their oncologists.

Conclusions and Relevance: In this study, patient-oncologist discordance about survival prognosis was common and patients rarely knew that their opinions differed from those of their oncologists.

Original languageEnglish (US)
Pages (from-to)1421-1426
Number of pages6
JournalJAMA oncology
Volume2
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Neoplasms
Survival
Oncologists
Communication
Decision Making
Cross-Sectional Studies
Outcome Assessment (Health Care)
Physicians

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gramling, R., Fiscella, K., Xing, G., Hoerger, M., Duberstein, P., Plumb, S., ... Epstein, R. M. (2016). Determinants of Patient-Oncologist Prognostic Discordance in Advanced Cancer. JAMA oncology, 2(11), 1421-1426. https://doi.org/10.1001/jamaoncol.2016.1861

Determinants of Patient-Oncologist Prognostic Discordance in Advanced Cancer. / Gramling, Robert; Fiscella, Kevin; Xing, Guibo; Hoerger, Michael; Duberstein, Paul; Plumb, Sandy; Mohile, Supriya; Fenton, Joshua J; Tancredi, Daniel J; Kravitz, Richard L; Epstein, Ronald M.

In: JAMA oncology, Vol. 2, No. 11, 01.11.2016, p. 1421-1426.

Research output: Contribution to journalArticle

Gramling, R, Fiscella, K, Xing, G, Hoerger, M, Duberstein, P, Plumb, S, Mohile, S, Fenton, JJ, Tancredi, DJ, Kravitz, RL & Epstein, RM 2016, 'Determinants of Patient-Oncologist Prognostic Discordance in Advanced Cancer', JAMA oncology, vol. 2, no. 11, pp. 1421-1426. https://doi.org/10.1001/jamaoncol.2016.1861
Gramling R, Fiscella K, Xing G, Hoerger M, Duberstein P, Plumb S et al. Determinants of Patient-Oncologist Prognostic Discordance in Advanced Cancer. JAMA oncology. 2016 Nov 1;2(11):1421-1426. https://doi.org/10.1001/jamaoncol.2016.1861
Gramling, Robert ; Fiscella, Kevin ; Xing, Guibo ; Hoerger, Michael ; Duberstein, Paul ; Plumb, Sandy ; Mohile, Supriya ; Fenton, Joshua J ; Tancredi, Daniel J ; Kravitz, Richard L ; Epstein, Ronald M. / Determinants of Patient-Oncologist Prognostic Discordance in Advanced Cancer. In: JAMA oncology. 2016 ; Vol. 2, No. 11. pp. 1421-1426.
@article{7315f719035a4199a36632e07fd79810,
title = "Determinants of Patient-Oncologist Prognostic Discordance in Advanced Cancer",
abstract = "Design, Setting, and Participants: Cross-sectional study conducted at academic and community oncology practices in Rochester, New York, and Sacramento, California. The sample comprises 236 patients with advanced cancer and their 38 oncologists who participated in a randomized trial of an intervention to improve clinical communication. Participants were enrolled from August 2012 to June 2014 and followed up until October 2015.Importance: Patients with advanced cancer often report expectations for survival that differ from their oncologists' expectations. Whether patients know that their survival expectations differ from those of their oncologists remains unknown. This distinction is important because knowingly expressing differences of opinion is important for shared decision making, whereas patients not knowing that their understanding differs from that of their treating physician is a potential marker of inadequate communication.Objective: To describe the prevalence, distribution, and proportion of prognostic discordance that is due to patients' knowingly vs unknowingly expressing an opinion that differs from that of their oncologist.Main Outcomes and Measures: We ascertained discordance by comparing patient and oncologist ratings of 2-year survival probability. For discordant pairs, we determined whether patients knew that their opinions differed from those of their oncologists by asking the patients to report how they believed their oncologists rated their 2-year survival.Results: Among the 236 patients (mean [SD] age, 64.5 [11.4] years; 54{\%} female), 161 patient-oncologist survival prognosis ratings (68{\%}; 95{\%} CI, 62{\%}-75{\%}) were discordant. Discordance was substantially more common among nonwhite patients compared with white patients (95{\%} [95{\%} CI, 86{\%}-100{\%}] vs 65{\%} [95{\%} CI, 58{\%}-73{\%}], respectively; P = .03). Among 161 discordant patients, 144 (89{\%}) did not know that their opinions differed from that of their oncologists and nearly all of them (155 of 161 [96{\%}]) were more optimistic than their oncologists.Conclusions and Relevance: In this study, patient-oncologist discordance about survival prognosis was common and patients rarely knew that their opinions differed from those of their oncologists.",
author = "Robert Gramling and Kevin Fiscella and Guibo Xing and Michael Hoerger and Paul Duberstein and Sandy Plumb and Supriya Mohile and Fenton, {Joshua J} and Tancredi, {Daniel J} and Kravitz, {Richard L} and Epstein, {Ronald M.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1001/jamaoncol.2016.1861",
language = "English (US)",
volume = "2",
pages = "1421--1426",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Determinants of Patient-Oncologist Prognostic Discordance in Advanced Cancer

AU - Gramling, Robert

AU - Fiscella, Kevin

AU - Xing, Guibo

AU - Hoerger, Michael

AU - Duberstein, Paul

AU - Plumb, Sandy

AU - Mohile, Supriya

AU - Fenton, Joshua J

AU - Tancredi, Daniel J

AU - Kravitz, Richard L

AU - Epstein, Ronald M.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Design, Setting, and Participants: Cross-sectional study conducted at academic and community oncology practices in Rochester, New York, and Sacramento, California. The sample comprises 236 patients with advanced cancer and their 38 oncologists who participated in a randomized trial of an intervention to improve clinical communication. Participants were enrolled from August 2012 to June 2014 and followed up until October 2015.Importance: Patients with advanced cancer often report expectations for survival that differ from their oncologists' expectations. Whether patients know that their survival expectations differ from those of their oncologists remains unknown. This distinction is important because knowingly expressing differences of opinion is important for shared decision making, whereas patients not knowing that their understanding differs from that of their treating physician is a potential marker of inadequate communication.Objective: To describe the prevalence, distribution, and proportion of prognostic discordance that is due to patients' knowingly vs unknowingly expressing an opinion that differs from that of their oncologist.Main Outcomes and Measures: We ascertained discordance by comparing patient and oncologist ratings of 2-year survival probability. For discordant pairs, we determined whether patients knew that their opinions differed from those of their oncologists by asking the patients to report how they believed their oncologists rated their 2-year survival.Results: Among the 236 patients (mean [SD] age, 64.5 [11.4] years; 54% female), 161 patient-oncologist survival prognosis ratings (68%; 95% CI, 62%-75%) were discordant. Discordance was substantially more common among nonwhite patients compared with white patients (95% [95% CI, 86%-100%] vs 65% [95% CI, 58%-73%], respectively; P = .03). Among 161 discordant patients, 144 (89%) did not know that their opinions differed from that of their oncologists and nearly all of them (155 of 161 [96%]) were more optimistic than their oncologists.Conclusions and Relevance: In this study, patient-oncologist discordance about survival prognosis was common and patients rarely knew that their opinions differed from those of their oncologists.

AB - Design, Setting, and Participants: Cross-sectional study conducted at academic and community oncology practices in Rochester, New York, and Sacramento, California. The sample comprises 236 patients with advanced cancer and their 38 oncologists who participated in a randomized trial of an intervention to improve clinical communication. Participants were enrolled from August 2012 to June 2014 and followed up until October 2015.Importance: Patients with advanced cancer often report expectations for survival that differ from their oncologists' expectations. Whether patients know that their survival expectations differ from those of their oncologists remains unknown. This distinction is important because knowingly expressing differences of opinion is important for shared decision making, whereas patients not knowing that their understanding differs from that of their treating physician is a potential marker of inadequate communication.Objective: To describe the prevalence, distribution, and proportion of prognostic discordance that is due to patients' knowingly vs unknowingly expressing an opinion that differs from that of their oncologist.Main Outcomes and Measures: We ascertained discordance by comparing patient and oncologist ratings of 2-year survival probability. For discordant pairs, we determined whether patients knew that their opinions differed from those of their oncologists by asking the patients to report how they believed their oncologists rated their 2-year survival.Results: Among the 236 patients (mean [SD] age, 64.5 [11.4] years; 54% female), 161 patient-oncologist survival prognosis ratings (68%; 95% CI, 62%-75%) were discordant. Discordance was substantially more common among nonwhite patients compared with white patients (95% [95% CI, 86%-100%] vs 65% [95% CI, 58%-73%], respectively; P = .03). Among 161 discordant patients, 144 (89%) did not know that their opinions differed from that of their oncologists and nearly all of them (155 of 161 [96%]) were more optimistic than their oncologists.Conclusions and Relevance: In this study, patient-oncologist discordance about survival prognosis was common and patients rarely knew that their opinions differed from those of their oncologists.

UR - http://www.scopus.com/inward/record.url?scp=85013093384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013093384&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2016.1861

DO - 10.1001/jamaoncol.2016.1861

M3 - Article

VL - 2

SP - 1421

EP - 1426

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

IS - 11

ER -